Caputo Damiano, Digiacomo Luca, Cascone Chiara, Pozzi Daniela, Palchetti Sara, Di Santo Riccardo, Quagliarini Erica, Coppola Roberto, Mahmoudi Morteza, Caracciolo Giulio
Department of Surgery, University Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161 Rome, Italy.
Cancers (Basel). 2020 Dec 30;13(1):93. doi: 10.3390/cancers13010093.
Simultaneous detection of multiple analytes from a single biological sample is gaining more attention in the development of more reliable and point-of-care diagnostic devices. We developed a multiplexed strategy that combined outcomes of clinical biomarkers with analysis of the protein corona that forms around graphene oxide sheets upon exposure to patient's plasma. As a paradigmatic case study, we selected pancreatic ductal adenocarcinoma (PDAC), mainly because of the absence of effective detection strategies that resulted in an extremely low five-year survival rate after diagnosis (<10%). Association of protein corona analysis and haemoglobin levels discriminated PDAC patients from healthy volunteers in up to 90% of cases. If further confirmed in larger-cohort studies, this approach may be used in the detection of PDAC.
在开发更可靠的即时诊断设备过程中，从单一生物样本中同时检测多种分析物正受到越来越多的关注。我们开发了一种多重策略，将临床生物标志物的检测结果与对氧化石墨烯片暴露于患者血浆后形成的蛋白质冠层的分析相结合。作为一个典型的案例研究，我们选择了胰腺导管腺癌（PDAC），主要是因为缺乏有效的检测策略，导致诊断后的五年生存率极低（<10%）。蛋白质冠层分析与血红蛋白水平的联合检测在高达90%的病例中能够区分PDAC患者和健康志愿者。如果在更大规模的队列研究中得到进一步证实，这种方法可用于PDAC的检测。
